WEBULL
WebtradeDownload

Is BioMarin Pharmaceutical (BMRN) Below Fair Value After New Clinical Data And Its AI Deal?

Simply Wall St · 1d ago

Fresh clinical data and an AI drug discovery deal have pushed BioMarin Pharmaceutical (BMRN) back into focus, as investors weigh what the latest Pompe and Duchenne updates might mean for the pipeline.

For all the fresh clinical headlines, BioMarin Pharmaceutical’s share price has been under pressure in recent weeks, with the stock down 17.03% over 30 days and 7.15% year to date. Even as the 1-year total shareholder return is slightly positive at 0.93%, this suggests recent momentum has faded while long-term holders have seen only modest change.

Consider how BioMarin Pharmaceutical fits into your biotech watchlist, then scan hand picked rare disease peers and adjacent opportunities across the 34 healthcare AI stocks that are leaning into AI driven drug discovery.

Bulls point to rare disease cash flows, fresh Pompe and Duchenne data, and new AI discovery tools. Bears focus on a sliding share price and past drawdowns. The key question is which side the current valuation of BioMarin Pharmaceutical appears to support.

Most Popular Narrative: 40% Undervalued

BioMarin Pharmaceutical last closed at $55.20 against a widely followed fair value estimate of $91.62, so the current share price sits well below what that framework suggests. This pushes the focus onto whether the rare disease portfolio and acquisitions can justify the gap.

Scaling a broader rare disease portfolio at BioMarin Pharmaceutical, with nine commercial therapies and management expectations that at least four products including VOXZOGO, GALAFOLD, POMBILITI+OPFOLDA and potentially VIMIZIM could each reach about 1b in annual sales, points to a larger revenue base that the current P/E may not fully reflect.

See why 42 investors see BioMarin Pharmaceutical as 40% undervalued.

Result: Fair Value of $91.62 (UNDERVALUED)

Still, the BioMarin Pharmaceutical story can break if promised margin gains from acquisitions fail to show up, or if a high P/E meets slower than expected earnings progress.

Find out about the key risks to this BioMarin Pharmaceutical narrative.

Another View: BioMarin Pharmaceutical Looks Expensive On Earnings

The earlier fair value of $91.62 leans on future cash flow expectations. A simple P/E check tells a very different story. BioMarin Pharmaceutical trades around 146.4x earnings, while US biotech peers average 16.9x and the fair ratio sits at 31x.

That gap suggests investors are paying a rich price per dollar of profit today, which raises the question of how much execution risk you are willing to accept if earnings forecasts shift.

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:BMRN P/E Ratio as at Oct 2026
NasdaqGS:BMRN P/E Ratio as at Oct 2026

Next Steps

Mixed messages on valuation and sentiment are clear, so move fast on the data, pressure test your own assumptions, and then weigh the 2 key rewards and 4 important warning signs.

Looking For More Investment Ideas Beyond BioMarin Pharmaceutical?

Do not stop with BioMarin Pharmaceutical. Use the Simply Wall Street Screener to spot other potential opportunities that match your style before the market moves first.

  • Target dependable cash generators by scanning a curated 29 high quality undervalued stocks that combines quality fundamentals with valuations that may appeal to value focused investors.
  • Strengthen your income shortlist by reviewing a focused 8 dividend fortresses that emphasises higher yields with supporting balance sheets.
  • Prioritise resilience by filtering through a tailored 31 resilient stocks with low risk scores built around businesses with lower risk profiles and steadier financial characteristics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.